Literature DB >> 9663595

BRCA1-related breast cancer in Austrian breast and ovarian cancer families: specific BRCA1 mutations and pathological characteristics.

T M Wagner1, R A Möslinger, D Muhr, G Langbauer, K Hirtenlehner, H Concin, W Doeller, A Haid, A H Lang, P Mayer, E Ropp, E Kubista, B Amirimani, T Helbich, A Becherer, O Scheiner, H Breiteneder, A Borg, P Devilee, P Oefner, C Zielinski.   

Abstract

We identified 17 BRCA1 mutations in 86 Austrian breast and ovarian cancer families (20%) that were screened for mutations by denaturing high-performance liquid chromatography (DHPLC) and the protein truncation test (PTT). Eleven distinct mutations were detected, 4 of them (962del4, 2795del4, 3135del4 and L3376stop) not previously reported in families of non-Austrian origin. In addition, 6 rare missense mutations (allele frequency < 1%) with unknown biological effects were identified. Four mutations occurred more than once in the Austrian population: 2795del4 (3 times), Cys61Gly (3 times) 5382insC (2 times) and Q1806stop (2 times). Haplotype analysis of the 4 recurrent mutations suggested a common ancestor for each of these. Thirty-four breast cancer cases from 17 families with BRCA1 mutations were further analyzed. We observed a low median age of onset (39.5 years). Sixty-eight percent of all BRCA1 breast cancer cases had negative axillary lymph nodes. This group showed a significant prevalence of a negative estrogen and progesterone receptor status and stage I tumors compared with an age-related, node-negative control group. The prevalence of grade III tumors was marginally significant. Survival analysis either with a control group matched for age (within 5 years), grade, histologic subtype and estrogen receptor status, or with an age-related, node-negative comparison group, showed no statistical difference.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9663595     DOI: 10.1002/(sici)1097-0215(19980729)77:3<354::aid-ijc8>3.0.co;2-n

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

Review 1.  Automated mutation analysis.

Authors:  D Ravine
Journal:  J Inherit Metab Dis       Date:  1999-06       Impact factor: 4.982

2.  Pre-test prediction models of BRCA1 or BRCA2 mutation in breast/ovarian families attending familial cancer clinics.

Authors:  M de la Hoya; O Díez; P Pérez-Segura; J Godino; J M Fernández; J Sanz; C Alonso; M Baiget; E Díaz-Rubio; T Caldés
Journal:  J Med Genet       Date:  2003-07       Impact factor: 6.318

Review 3.  Mutations in context: implications of BRCA testing in diverse populations.

Authors:  Gabriela E S Felix; Yonglan Zheng; Olufunmilayo I Olopade
Journal:  Fam Cancer       Date:  2018-10       Impact factor: 2.375

4.  Validation of denaturing high performance liquid chromatography as a rapid detection method for the identification of human INK4A gene mutations.

Authors:  I Orlow; P Roy; A Barz; R Canchola; Y Song; M Berwick
Journal:  J Mol Diagn       Date:  2001-11       Impact factor: 5.568

Review 5.  The contribution of inherited factors to the clinicopathological features and behavior of breast cancer.

Authors:  W D Foulkes; J Rosenblatt; P O Chappuis
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-10       Impact factor: 2.673

6.  High prevalence of BRCA1 stop mutation c.4183C>T in the Tyrolean population: implications for genetic testing.

Authors:  Laura Pölsler; Heidi Fiegl; Katharina Wimmer; Willi Oberaigner; Albert Amberger; Pia Traunfellner; Raphael J Morscher; Ingrid Weber; Christine Fauth; Annekatrin Wernstedt; Barbara Sperner-Unterweger; Anne Oberguggenberger; Michael Hubalek; Christian Marth; Johannes Zschocke
Journal:  Eur J Hum Genet       Date:  2015-05-27       Impact factor: 4.246

7.  The occurrence of germline BRCA1 and BRCA2 sequence alterations in Slovenian population.

Authors:  Vida Stegel; Mateja Krajc; Janez Zgajnar; Erik Teugels; Jacques De Grève; Marko Hočevar; Srdjan Novaković
Journal:  BMC Med Genet       Date:  2011-01-14       Impact factor: 2.103

8.  High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area.

Authors:  Petr Pohlreich; Michal Zikan; Jana Stribrna; Zdenek Kleibl; Marketa Janatova; Jaroslav Kotlas; Jana Zidovska; Jan Novotny; Lubos Petruzelka; Csilla Szabo; Bohuslav Matous
Journal:  Breast Cancer Res       Date:  2005-07-19       Impact factor: 6.466

9.  Estimates of the likely prophylactic effect of tamoxifen in women with high risk BRCA1 and BRCA2 mutations.

Authors:  S W Duffy; R M Nixon
Journal:  Br J Cancer       Date:  2002-01-21       Impact factor: 7.640

10.  Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control.

Authors:  Ramūnas Janavičius
Journal:  EPMA J       Date:  2010-06-27       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.